Stocks · News reference
Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).
Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug Program